FrancophonIA/ELRC3.0 huggingface dataset:
English: While changes in laboratory values were observed in some patients treated with Rebetol used in combination with peginterferon alfa-2b in the clinical trial, values returned to baseline levels within a few weeks after the end of therapy.
Danish: Selv om der blev observeret ændringer i laboratorieværdier hos nogle patienter behandlet med Rebetol anvendt i kombination med peginterferon alfa-2b i kliniske forsøg, vendte værdierne tilbage til baseline niveau inden for et par uger efter afslutningen af behandlingen.
English: Bacterial infection (including sepsis), fungal infection, influenza, respiratory tract infection, bronchitis, herpes simplex, sinusitis, otitis media, rhinitis, urinary tract infection
Danish: Bakterieinfektion (inklusive sepsis), svampeinfektion, influenza, luftvejsinfektion, bronkitis, herpes simplex, sinuitis, otitis media, rinitis, urinvejsinfektion
English: In a separate trial, 224 patients with genotype 2 or 3 received peginterferon alfa-2b, 1.5 microgram/kg subcutaneously, once weekly, in combination with ribavirin 800 mg -1,400 mg p.o. for 6 months (based on body weight, only three patients weighing > 105 kg, received the 1,400 mg dose) (Table 8).
Danish: I en separat undersøgelse fik 224 patienter med genotype 2 eller 3 peginterferon alfa-2b, 1,5 mikrogram/kg subkutant en gang ugentligt i kombination med Rebetol 800 mg -1.400 mg p.o. i 6 måneder (baseret på legemsvægt, kun tre patienter, der vejede > 105 kg, fik 1.400 mg dosen) (Tabel 8).
English: Cerebrovascular haemorrhage*, cerebrovascular ischaemia*, encephalopathy*, polyneuropathy*
Danish: Cerebrovaskulær blødning٭, cerebrovaskulær iskæmi٭ hjernebetændelse٭, polyneuropati٭
English: Do not throw away any medicines via wastewater or household waste.
Danish: Af hensyn til miljøet må du ikke smide medicinrester i afløbet eller, toilettet eller skraldespanden.
English: Rebetol in combination with Direct Antiviral Agent (DAA):
Danish: Rebetol i kombination med direkte virkende antivirale lægemidler:
English: In females of childbearing potential, Rebetol must not be initiated until a report of a negative pregnancy test has been obtained immediately prior to initiation of therapy.
Danish: Hos kvinder i den fertile alder må Rebetol ikke initieres, før et negativt resultat fra en graviditetstest er opnået umiddelbart før behandlingsstart.
English: Vertigo, hearing impaired/loss, tinnitus, ear pain
Danish: Vertigo, nedsat/tab hørelse, tinnitus, øresmerter
English: Do not store above 30ºC.
Danish: Må ikke opbevares ved temperaturer over 30ºC.
English: Genotype 1  600,000 IU/mL
Danish: Genotype 1  600.000 IE/ml
English: SVR after treatment of chronic HCV with interferon alfa-2b (pegylated and non-pegylated, with or without Rebetol) results in long-term clearance of the virus providing resolution of the hepatic infection and clinical 'cure' from chronic HCV.
Danish: SVR efter behandling af kronisk HCV med interferon alfa-2b (pegyleret eller non-pegyleret, med eller uden Rebetol) resulterer i langtidsclearance af virus, hvilket medfører resolution af den leverinfektion og klinisk 'helbredelse' af kronisk HCV.
English: A reduction in haemoglobin concentrations by > 4 g/dL was observed in 30 % of patients treated with Rebetol and peginterferon alfa-2b and 37 % of patients treated with Rebetol and interferon alfa-2b.
Danish: Et fald i hæmoglobinkoncentration på > 4g/dl blev set hos 30 % af patienter behandlet med Rebetol og peginterferon alfa-2b og 37 % af patienter behandlet med Rebetol og interferon alfa-2b.
English: Also, refer to peginterferon alfa-2b and interferon alfa-2b SmPCs for adverse reactions that may be attributable to interferons monotherapy.
Danish: Desuden refererer SmPC'et for peginterferon alfa2b og interferon alfa-2b til bivirkninger, der kan tilskrives interferoners monoterapi.
English: Some data suggest that HIV/HCV co-infected patients receiving abacavir-containing ART may be at risk of a lower response rate to pegylated interferon/Rebetol therapy.
Danish: Nogle data tyder på, at hiv/HCV-co-inficerede patienter, der får abacavir-holdig ARbehandling, kan være i risiko for respondere dårligere på pegyleret interferon/Rebetol-behandling.
English: Rebetol (800 mg/day)
Danish: Rebetol (800 mg)
English: Patients were randomized to receive either Rebetol (800 mg/day) plus peginterferon alfa-2b (1.5 µg/kg/week) or Rebetol (800 mg/day) plus interferon alfa-2b (3 MIU TIW) for 48 weeks with a follow-up period of 6 months.
Danish: Patienterne blev randomiseret til enten at modtage Rebetol (800 mg/dag) plus peginterferon alfa-2b (1,5 μg/kg/uge) eller Rebetol (800 mg/dag) plus interferon alfa-2b (3-MIE TIW) i 48 uger med en opfølgningsperiode på 6 måneder.
English: The recommended dose and duration of Rebetol depends on how much the patient weighs and the medicines that are used in combination.
Danish: Den anbefalede dosis og behandlingsvarighed af Rebetol afhænger af, hvor meget patienten vejer, og hvilken medicin som anvendes i kombinationsbehandlingen.
English: Table 7 Sustained virological response: previously untreated children and adolescents Rebetol 15 mg/kg/day interferon alfa-2b 3 MIU/m2 3 times a week
Danish: Tabel 7 Vedvarende virologisk respons: Tidligere ubehandlede børn og unge Rebetol 15 mg/kg/dag interferon alfa-2b 3 MIE/m2 3 gange om ugen
English: The use of Rebetol in combination treatment with peginterferon alfa-2b or interferon alfa-2b was evaluated in a number of clinical trials.
Danish: Anvendelsen af Rebetol i kombinationsbehandling med peginterferon alfa-2b eller interferon alfa-2b blev vurderet i en række kliniske undersøgelser.
English: No interaction studies have been conducted with Rebetol and other medicinal products, except for interferon alfa-2b and antacids.
Danish: Ingen interaktionsundersøgelser er udført med Rebetol og andre lægemidler med undtagelse af interferon alfa-2b og antacida.
English: Please refer to the corresponding SmPC of the antiretroviral medicinal products that are to be taken concurrently with HCV therapy for awareness and management of toxicities specific for each product and the potential for overlapping toxicities with Rebetol in combination with other medicinal products.
Danish: Der henvises til SmPC for de antiretrovirale lægemidler, der skal tages samtidig ved HCV-behandling, for bevidsthed om og håndtering af toksicitet, der er specifik for det enkelte produkt, samt for potentiale for overlappende toksicitet med Rebetol i kombination med andre lægemidler.
English: Rebetol may be used in paediatric patients (children 3 years of age and older and adolescents) who are not previously treated and without severe liver disease.
Danish: Rebetol kan anvendes hos tidligere ubehandlede børn og unge (børn i alderen 3 år og ældre samt unge) uden alvorlig leversygdom.
English: Anaemia (haemoglobin < 9.4 g/dL) was reported in 12 % (23/194) of patients treated with Rebetol in combination with peginterferon alfa-2b.
Danish: (hæmoglobin < 9,4 g/dl) blev rapporteret i 12 % (23/194) af patienterne, der blev behandlet med Rebetol i kombination med peginterferon alfa-2b.
English: In a juvenile rat toxicity study, pups dosed from postnatal day 7 to 63 with 10, 25 and 50 mg/kg of ribavirin demonstrated a dose-related decrease in overall growth, which was subsequently manifested as slight decreases in body weight, crown-rump length and bone length.
Danish: I en toksicitetsundersøgelse med rotter viste unger, der fik ribavirin 10, 25 og 50 mg/kg fra postnatal dag 7 til 63, et dosisrelateret fald i samlet vækst.
English: Each hard capsule contains 200 mg of ribavirin.
Danish: Hver hård kapsel indeholder 200 mg ribavirin.
English: Rebetol 40 mg/mL oral solution
Danish: Rebetol 40 mg/ml oral opløsning
English: In a non-comparative trial, 235 patients with genotype 1 and low viral load (< 600,000 IU/mL) received peginterferon alfa-2b, 1.5 microgram/kg subcutaneously, once weekly, in combination with weight adjusted Rebetol.
Danish: I et ikke-sammenlignende studie fik 235 patienter med genotype 1 og lav virusmængde (< 600.000 IE/ml) peginterferon alfa-2b 1,5 mikrogram/kg subkutant en gang ugentlig i kombination med vægtjusteret Rebetol.
English: United Kingdom Merck Sharp & Dohme Limited Tel: +44 (0) 1992 467272 medicalinformationuk@merck.com
Danish: Merck Sharp & Dohme Limited Tel: +44 (0) 1992 467272 medicalinformationuk@merck.com
English: Haemolitic anaemia, leukopenia, thrombocytopenia, lymphadenopathy, lymphopenia
Danish: Hæmolytisk anæmi, leukopeni, trombocytopeni, lymfadenopati, lymfopeni
English: Hypertriglyceridemia, hyperuricemia
Danish: Hypertriglyceridæmi, hyperurikæmi
English: Hepatic decompensation in HCV/HIV co-infected patients with advanced cirrhosis Co-infected patients with advanced cirrhosis receiving combined anti-retroviral therapy (cART) may be at increased risk of hepatic decompensation and death.
Danish: Leverdekompensation hos HCV/hiv co-inficerede patienter med fremskreden cirrose Patienter med samtidig HCV/hiv-infektion og fremskreden cirrose, som får antiretroviral kombinationsbehandling (cART), kan have en øget risiko for nedsat leverfunktion og død.
English: Reminder: Please read the “Do not take” section of the Package Leaflet for the other medicines used in combination with this medicine.
Danish: Bemærk: Læs afsnittet ”Tag ikke” i indlægssedlen for de andre lægemidler, som anvendes sammen med dette lægemiddel.
English: • Rebetol (1,000/1,200 mg/day) + interferon alfa-2b (3 MIU three times a week) (n = 505).
Danish: • Rebetol (1.000/1.200 mg/dag) + interferon alfa-2b (3 MIE tre gange om ugen) (n = 505).
English: Malformations of the skull, palate, eye, jaw, limbs, skeleton and gastrointestinal tract were noted.
Danish: Misdannelser af kranium, gane, øje, kæbe, lemmer, skelet og mavetarm kanal blev registreret.
English: - The active substance is ribavirin 40 mg/mL.
Danish: Rebetol indeholder - Aktivt stof: Ribavirin 40 mg/ml.
English: In a non-comparative trial, 2,293 patients with moderate to severe fibrosis who failed previous treatment with combination alpha interferon/ribavirin were retreated with peginterferon alfa-2b, 1.5 microgram/kg subcutaneously, once weekly, in combination with weight adjusted Rebetol.
Danish: 2.293 patienter i en ikke sammenligningsundersøgelse, som havde moderat til svær fibrose, hvor tidligere behandling med kombinationen af alfa interferon/ribavirin var uden effekt, blev behandlet med peginterferon alfa-2b givet subkutant (1,5 mikrogram/kg/uge) i kombination med Rebetol baseret på legemsvægt.
English: The adverse reactions listed in this section are primarily derived from clinical trials and/or as adverse drug reactions from spontaneous reports when Rebetol was used in combination with interferon alfa-2b or peginterferon alfa-2b.
Danish: De bivirkninger, som er angivet i dette afsnit, er primært rapporteret fra kliniske studier og/eller som bivirkninger fra spontane rapporter, når Rebetol blev brugt i kombination med interferon alfa-2b eller peginterferon alfa-2b.
English: Conventional carcinogenicity rodent studies with low exposures compared to human exposure under therapeutic conditions (factor 0.1 in rats and 1 in mice) did not reveal tumorigenicity of ribavirin.
Danish: Ribavirin blev ikke fundet tumorfremkaldende i konventionelle karcinogenicitetsundersøgelser på gnavere med lav eksponering sammenlignet med human eksponering under terapeutiske omstændigheder (faktor 0,1 i rotter og 1 i mus).
English: P1.5/R Rebetol (800 mg) + peginterferon alfa-2b (1.5 micrograms/kg) P0.5/R Rebetol (1,000/1,200 mg) + peginterferon alfa-2b (1.5 to 0.5 microgram/kg) I/R
Danish: P1,5/R Rebetol (800 mg) + peginterferon alfa-2b (1,5 mikrogram/kg) P0,5/R Rebetol (1.000/1.200 mg) + peginterferon alfa-2b (1,5 til 0,5 mikrogram/kg) I/R
English: Patients were randomized to receive either Rebetol (800-1,200 mg/day based on weight) plus peginterferon alfa-2b (100 or 150 µg/week based on weight) or Rebetol (800-1,200 mg/day based on weight) plus interferon alfa-2b (3 MIU TIW).
Danish: Patienterne blev randomiseret til enten at modtage Rebetol (800-1.200 mg/dag baseret på vægt) plus peginterferon alfa-2b (100 eller 150 μg/uge baseret på vægt) eller Rebetol (800-1.200 mg/dag baseret på vægt) plus interferon alfa-2b (3 MIE TIW).
English: Merck Sharp & Dohme Romania S.R.L.
Danish: România Merc Merck Sharp & Dohme Romania S.R.L.
English: Rebetol must not be used by females who are pregnant (see sections 4.3 and 5.3).
Danish: Rebetol må ikke anvendes af gravide kvinder (se pkt.
English: Multiple-dose pharmacokinetic properties for Rebetol capsules and interferon alfa-2b in children and adolescents with chronic hepatitis C between 5 and 16 years of age are summarized in Table 8.
Danish: Flerdosis farmakokinetiske egenskaber for Rebetol kapsler og interferon alfa-2b hos børn og unge med kronisk hepatitis C i alderen 5 til 16 år er opsummeret i Tabel 8.
English: In the treatment phase of this study, the most prevalent adverse reactions in all subjects were pyrexia (80 %), headache (62 %), neutropenia (33 %), fatigue (30 %), anorexia (29 %) and injection site erythema (29 %).
Danish: I behandlingsfasen af dette studie var den mest udbredte bivirkning hos alle forsøgspersonerne var feber (80 %), hovedpine (62 %), neutropeni (33 %), træthed (30 %), anoreksi (29 %) og injektionskoncentration-site erytem (29 % ).
English: In clinical trials with Rebetol used in combination with interferon alfa-2b, the maximum overdose reported was a total dose of 10 g of Rebetol (50 x 200 mg capsules) and 39 MIU of interferon alfa-2b (13 subcutaneous injections of 3 MIU each) taken in one day by a patient in an attempt at suicide.
Danish: I kliniske undersøgelser med Rebetol anvendt i kombination med interferon alfa-2b var den højeste rapporterede overdosering en total dosis på 10 g Rebetol (50 x 200 mg kapsler) og 39 MIE interferon alfa2b (13 subkutane injektioner med 3 MIE hver) anvendt på en dag af en patient i forsøg på selvmord.
English: Table 1 Rebetol dose based on body weight when used in combination with interferon alfa-2b or peginterferon alfa-2b in paediatric patients Patient weight (kg)
Danish: Tabel 1 Rebetol-dosis baseret på legemsvægt i kombination med interferon alfa-2b eller peginterferon alfa-2b hos pædiatriske patienter Patientvægt (kg)
English: - Genotoxicity: Rebetol induces genotoxicity (see section 5.3).
Danish: Genotoksicitet: Rebetol bevirker genotoksicitet (se pkt.
English: • Rebetol (1,000/1,200 mg/day) + peginterferon alfa-2b (1.5 micrograms/kg/week for one month followed by 0.5 microgram/kg/week for 11 months) (n = 514).
Danish: • Rebetol (1.000/1.200 mg/dag) + peginterferon alfa-2b (1,5 mikrogram/kg/uge i en måned efterfulgt af 0,5 mikrogram/kg/uge i 11 måneder) (n = 514).
English: SVR after treatment of chronic HCV with non-pegylated interferon alfa-2b with Rebetol results in long-term clearance of the virus providing resolution of the hepatic infection and clinical 'cure' from chronic HCV.
Danish: SVR efter behandling af kronisk HCV med ikke-pegyleret interferon alfa-2b med Rebetol resulterede i langtids-clearance af virus, som resulterede i opløsning af den leverinfektion og klinisk 'helbredelse' af kronisk HCV.
English: Table 14 Sustained virological response in previously untreated children and adolescents Rebetol 15 mg/kg/day interferon alfa-2b 3 MIU/m2 3 times a week
Danish: Tabel 14 Vedvarende virologisk respons: Tidligere ubehandlede børn og unge Rebetol 15 mg/kg/dag interferon alfa-2b 3 MIE/m2 3 gange om ugen
English: Rebetol therapy must not be initiated until a report of a negative pregnancy test has been obtained immediately prior to initiation of therapy.
Danish: Behandling med Rebetol må kun initieres, når der foreligger en negativ graviditetstest umiddelbart før behandlingsstart.
English: • Dental and periodontal disorders: Dental and gum disorders have been reported in patients receiving Rebetol in combination with (peg)interferon alfa-2b.
Danish: • Tand- og tandkødssygdomme: Tand- og tandkødssygdomme er set hos patienter, som er blevet behandlet med Rebetol og peginterferon alfa-2b samtidig.
English: Rebetol 200 mg capsules ribavirin
Danish: Rebetol 200 mg kapsler ribavirin
English: Table 8 Mean (% CV) multiple-dose pharmacokinetic parameters for interferon alfa-2b and Rebetol capsules when administered to paediatric patients with chronic hepatitis C PARAMETER
Danish: Tabel 8 Gennemsnitlig (% CV) flerdosis farmakokinetiske parametre for interferon alfa-2b og Rebetol kapsler ved administration til pædiatriske patienter med kronisk hepatitis C PARAMETER
English: No interaction studies have been conducted with Rebetol and other medicinal products, except for peginterferon alfa-2b, interferon alfa-2b and antacids.
Danish: Ingen interaktionsundersøgelser er udført med Rebetol og andre lægemidler med undtagelse af peginterferon alfa-2b, interferon alfa-2b og antacida.
English: HCV-RNA negative
Danish: (n=950) HCV-RNA negative
English: Not known side effects (frequency cannot be estimated from the available data): thoughts about threatening the life of others, mania (excessive or unreasonable enthusiasm), pericarditis (inflammation of the lining of the heart), pericardial effusion [a fluid collection that develops between the pericardium (the lining of the heart) and the heart itself], change in colour of the tongue.
Danish: Ikke kendte bivirkninger (hyppighed kan ikke vurderes ud fra tilgængelige data): - tanker om at true andre på livet, - mani (unormalt stor eller unødvendig entusiasme) - perikarditis (betændelse i hjertesækken), perikardial effusion [en væskeansamling, der udvikles mellem perikardium (hjertesækken) og selve hjertet], - ændring i tungens farve.
English: Table 8 Virologic Response at End of Treatment, Sustained Virologic Response and Relapse by HCV Genotype and Viral Load* Rebetol 800-1,400 mg/day plus peginterferon alfa-2b 1.5 g/kg once weekly End of Treatment Response
Danish: Virologisk respons ved afsluttet behandling, vedvarende virologisk respons og relaps efter HCV-genotype og virusmængde* peginterferon alfa-2b 1,5 g/kg en gang ugentlig plus Rebetol 8001.400 mg/dag
English: Rebetol is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) for paediatric patients (children 3 years of age and older and adolescents) not previously treated and without liver decompensation (see sections 4.2, 4.4 and 5.1).
Danish: Rebetol er i kombination med andre lægemidler indiceret til behandling af kronisk hepatitis C hos tidligere ubehandlede pædiatriske patienter (børn i alderen 3 år og ældre samt unge) uden leverdekompensation (se pkt.
English: Children and adolescents 3 to 16 years of age with compensated chronic hepatitis C and detectable HCV-RNA (assessed by a central laboratory using a research-based RT-PCR assay) were enrolled in two multicentre trials and received Rebetol 15 mg/kg per day plus interferon alfa-2b 3 MIU/m 3 times a week for 1 year followed by 6 months follow-up after treatment.
Danish: Børn og unge i alderen 3 til 16 år med kompenseret kronisk hepatitis C og påviselig HCV RNA (målt hos et centralt laboratorium ved brug af en forskningsbaseret RT-PCR analyse) blev inkluderet i to multicenter undersøgelser og fik Rebetol 15 mg/kg per dag plus interferon alfa-2b 3 MIE/m2 tre gange om ugen i 1 år efterfulgt af 6 måneders opfølgning efter behandling.
English: Each capsule contains 200 mg of ribavirin.
Danish: Hver kapsel indeholder 200 mg ribavirin.
English: Information on excipients
Danish: Information om hjælpestoffer
English: Haematological abnormalities in HCV/HIV co-infected patients HCV/HIV co-infected patients receiving peginterferon alfa-2b/ribavirin treatment and cART may be at increased risk to develop haematological abnormalities (as neutropenia, thrombocytopenia and anaemia) compared to HCV mono-infected patients.
Danish: Hæmatologiske unormaliteter hos patienter med samtidig HCV/hiv-infektion Patienter, der samtidig er inficeret med HCV/hiv og som modtager peginterferon alfa-2b/ribavirin behandling og cART kan have øget risiko for at udvikle hæmatologiske unormaliteter (som neutropeni, trombocytopeni og anæmi) sammenlignet med HCV mono-inficerede patienter.
English: Table 3 provides guidelines for dose modification for patients with renal dysfunction.
Danish: Tabel 3 viser retningslinjer for dosisjustering for patienter med nedsat nyrefunktion.
English: For HCV/HIV co-infected patients receiving Rebetol in combination with peginterferon alfa-2b, other adverse reactions (that were not reported in mono-infected patients) which have been reported in the studies with a frequency > 5 % were: oral candidiasis (14 %), lipodystrophy acquired (13 %), CD4 lymphocytes decreased (8 %), appetite decreased (8 %), gamma-glutamyltransferase increased (9 %), back pain (5 %), blood amylase increased (6 %), blood lactic acid increased (5 %), cytolytic hepatitis (6 %), lipase increased (6 %) and pain in limb (6 %).
Danish: Bivirkningerne, der har været rapporteret i undersøgelserne med en hyppighed > 5 % var: oral candidiasis (14 %), pådraget lipodystrofi (13 %), nedsat CD4-lymfocytter (8 %), nedsat appetit (8 %), øget gammaglutamyltransferase (9 %), rygsmerter (5 %), øget amylase i blodet (6 %), øget mælkesyre i blodet (5 %), cytolytisk hepatitis (6 %), øget lipase (6 %) og smerte i lemmerne (6 %).
English: Table 5 Adverse reactions reported during clinical trials or following the marketing use of Rebetol with pegylated interferon alfa-2b or interferon alfa-2b System Organ Class
Danish: Tabel 5 Bivirkninger set i kliniske undersøgelser og efter markedsføring af Rebetol med pegyleret interferon alfa-2b eller interferon alfa-2b Systemorganklasse
English: Multiple-dose pharmacokinetic properties for Rebetol capsules and interferon alfa-2b in children and adolescents with chronic hepatitis C between 5 and 16 years of age are summarized in Table 15.
Danish: Flerdosis farmakokinetiske egenskaber for Rebetol kapsler og interferon alfa-2b hos børn og unge med kronisk hepatitis C i alderen 5 til 16 år er opsummeret i Tabel 15.
English: For use in patients with decompensated cirrhosis, see the corresponding SmPC of the medicinal products used in combination with Rebetol.
Danish: Ved brug hos patienter med dekompenseret cirrose henvises til SmPC'erne for de lægemidler, der anvendes i kombination med Rebetol.
English: Please refer to the corresponding SmPC of medicinal products used in combination with Rebetol as some combination regimens do not adhere to the Rebetol dosing guidance provided in Table 1.
Danish: Der henvises til SmPC'erne for de lægemidler, der anvendes i kombination med Rebetol, da visse kombinationsregimer ikke følger de doseringsanbefalinger for Rebetol, som er angivet i Tabel 1.
English: In clinical trials with Rebetol used in combination with peginterferon alfa-2b or interferon alfa-2b, the maximum overdose reported was a total dose of 10 g of Rebetol (50 x 200 mg capsules) and 39 MIU of interferon alfa-2b (13 subcutaneous injections of 3 MIU each) taken in one day by a patient in an attempt at suicide.
Danish: I kliniske undersøgelser med Rebetol anvendt i kombination med peginterferon alfa-2b eller interferon alfa-2b var den højeste rapporterede overdosering en total dosis på 10 g Rebetol (50 x 200 mg kapsler) og 39 MIE interferon alfa-2b (13 subkutane injektioner med 3 MIE hver) anvendt på en dag af en patient i forsøg på selvmord.
English: Psychiatric disorders Very common:
Danish: Psykiske forstyrrelser Meget almindelig:
English: Endocrine disorders Very common:
Danish: Det endokrine system Meget almindelig:
English: Please refer to the corresponding SmPC of medicinal products used in combination with Rebetol for discontinuation or dose modification recommendations.
Danish: Der henvises til SmPC'erne for de lægemidler, der anvendes i kombination med Rebetol, for anbefalinger vedrørende behandlingsafbrydelse eller dosisjustering.
English: The recommended dose and duration of Rebetol depends on patient's weight and on the medicinal product that is used in combination.
Danish: Den anbefalede dosis og behandlingsvarighed af Rebetol er afhængig af patientens legemsvægt og af, hvilke lægemidler der anvendes i kombinationsbehandlingen .